AstraZeneca: gets positive opinion from EU agency
(CercleFinance.com) - AstraZeneca and Merck said the European Medicines Agency (EMA) panel has recommended a marketing authorisation of Lynparza tablets for use as a maintenance therapy for patients with ovarian cancer.
The CHMP recommendation is based on two randomised trials which showed that Lynparza reduced the risk of disease progression or death for platinum-sensitive relapsed patients compared to placebo, the companies said.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The CHMP recommendation is based on two randomised trials which showed that Lynparza reduced the risk of disease progression or death for platinum-sensitive relapsed patients compared to placebo, the companies said.
Copyright (c) 2018 CercleFinance.com. All rights reserved.